Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vx-006 in HLA-A02 Positive Solid Tumors
NCT02289196Phase 1Completed
- Sponsor
- Vaxon Biotech
- Start
- Mar 2014
- Primary completion
- Oct 2014
- Modality
- Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of VX-006 in solid tumor (4 arms), sponsored by Vaxon Biotech. Primary endpoint: Adverse event number by treatment group at 18 weeks. Started Mar 2014; status: completed.
02
Drugs
VX-006
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02289196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289196.